神经科

订阅

MedSci主页 / 所有栏目 / 神经科

ADAA 2016：CRHR1受体拮抗剂对PTSD女性患者无效

2016-04-05 Mechront 译 MedSci原创

CRHR1PTSD肾上腺
关注

美国焦虑和抑郁协会年会上称，促肾上腺皮质激素1型受体拮抗剂（CRHR1受体拮抗剂）对创伤后应激障碍（PTSD）女性无效。为评估CRHR1拮抗剂GSK561679对PTSD患者的的临床有效应，研究者将符合DSM-IV标准的PTSD女性随机分为GSK561679 (n = 63)或安慰剂(n = 65)组，进行长达6周的治疗。纳入研究的参与者年龄18-65岁不等，医生管理PTSD量表(CAPS)得分均

美国焦虑和抑郁协会年会上称，促肾上腺皮质激素1型受体拮抗剂（CRHR1受体拮抗剂）对创伤后应激障碍（PTSD）女性无效。

为评估CRHR1拮抗剂GSK561679对PTSD患者的的临床有效应，研究者将符合DSM-IV标准的PTSD女性随机分为GSK561679 (n = 63)或安慰剂(n = 65)组，进行长达6周的治疗。纳入研究的参与者年龄18-65岁不等，医生管理PTSD量表(CAPS)得分均≥50岁，并且没有服用任何精神药物。

研究数据显示，从纳入研究到治疗终点，PTSD患者的CAPS得分在两组间无显著差异，此外自我报道的PTSD症状量表结果在两组间也没有差异。Montgomery-Asberg抑郁量表评估（MADS）结果在两组间无差异。对CAPS≥80分的亚组进行分析，GSK561679组和安慰剂组的有效性无差异。校正童年期创伤程度后，两组间的结果没有变化。不良反应事件在两组间无差异。

研究者写道：“研究结果表明，GSK561679对PTSD患者的症状改善无效，所以通过CRHR1受体拮抗剂调节的肾上腺系统可能不是治疗该疾病有效的机制。”

原始出处：

CRHR1 antagonist ineffective for PTSD in women.Healio.April 4, 2016

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2033496, encodeId=84e32033496cc, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Mon Oct 03 18:22:00 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779012, encodeId=14811e790124a, content=<a href='/topic/show?id=0a3d193085' target=_blank style='color:#2F92EE;'>#ADAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1930, encryptionId=0a3d193085, topicName=ADAA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Mon Jul 25 21:22:00 CST 2016, time=2016-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128603, encodeId=682612860393, content=不错哦，会学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 16 11:52:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264559, encodeId=54a9126455924, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Apr 07 04:22:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361809, encodeId=921d1361809ab, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5647, encryptionId=a88b564ea6, topicName=DAA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Apr 07 04:22:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511641, encodeId=547815116412a, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu Apr 07 04:22:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76070, encodeId=a890e60700c, content=学习了，很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Apr 06 15:55:00 CST 2016, time=2016-04-06, status=1, ipAttribution=)]
    2016-10-03 jiangfeng5067

    #女性患者#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2033496, encodeId=84e32033496cc, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Mon Oct 03 18:22:00 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779012, encodeId=14811e790124a, content=<a href='/topic/show?id=0a3d193085' target=_blank style='color:#2F92EE;'>#ADAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1930, encryptionId=0a3d193085, topicName=ADAA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Mon Jul 25 21:22:00 CST 2016, time=2016-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128603, encodeId=682612860393, content=不错哦，会学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 16 11:52:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264559, encodeId=54a9126455924, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Apr 07 04:22:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361809, encodeId=921d1361809ab, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5647, encryptionId=a88b564ea6, topicName=DAA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Apr 07 04:22:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511641, encodeId=547815116412a, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu Apr 07 04:22:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76070, encodeId=a890e60700c, content=学习了，很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Apr 06 15:55:00 CST 2016, time=2016-04-06, status=1, ipAttribution=)]
    2016-07-25 xinxin088

    #ADAA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2033496, encodeId=84e32033496cc, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Mon Oct 03 18:22:00 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779012, encodeId=14811e790124a, content=<a href='/topic/show?id=0a3d193085' target=_blank style='color:#2F92EE;'>#ADAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1930, encryptionId=0a3d193085, topicName=ADAA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Mon Jul 25 21:22:00 CST 2016, time=2016-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128603, encodeId=682612860393, content=不错哦，会学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 16 11:52:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264559, encodeId=54a9126455924, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Apr 07 04:22:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361809, encodeId=921d1361809ab, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5647, encryptionId=a88b564ea6, topicName=DAA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Apr 07 04:22:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511641, encodeId=547815116412a, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu Apr 07 04:22:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76070, encodeId=a890e60700c, content=学习了，很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Apr 06 15:55:00 CST 2016, time=2016-04-06, status=1, ipAttribution=)]
    2016-09-16 1e10c84am36(暂无匿称)

    不错哦，会学到很多

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2033496, encodeId=84e32033496cc, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Mon Oct 03 18:22:00 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779012, encodeId=14811e790124a, content=<a href='/topic/show?id=0a3d193085' target=_blank style='color:#2F92EE;'>#ADAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1930, encryptionId=0a3d193085, topicName=ADAA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Mon Jul 25 21:22:00 CST 2016, time=2016-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128603, encodeId=682612860393, content=不错哦，会学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 16 11:52:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264559, encodeId=54a9126455924, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Apr 07 04:22:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361809, encodeId=921d1361809ab, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5647, encryptionId=a88b564ea6, topicName=DAA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Apr 07 04:22:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511641, encodeId=547815116412a, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu Apr 07 04:22:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76070, encodeId=a890e60700c, content=学习了，很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Apr 06 15:55:00 CST 2016, time=2016-04-06, status=1, ipAttribution=)]
    2016-04-07 般若傻瓜

    #ADA#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2033496, encodeId=84e32033496cc, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Mon Oct 03 18:22:00 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779012, encodeId=14811e790124a, content=<a href='/topic/show?id=0a3d193085' target=_blank style='color:#2F92EE;'>#ADAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1930, encryptionId=0a3d193085, topicName=ADAA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Mon Jul 25 21:22:00 CST 2016, time=2016-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128603, encodeId=682612860393, content=不错哦，会学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 16 11:52:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264559, encodeId=54a9126455924, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Apr 07 04:22:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361809, encodeId=921d1361809ab, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5647, encryptionId=a88b564ea6, topicName=DAA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Apr 07 04:22:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511641, encodeId=547815116412a, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu Apr 07 04:22:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76070, encodeId=a890e60700c, content=学习了，很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Apr 06 15:55:00 CST 2016, time=2016-04-06, status=1, ipAttribution=)]
    2016-04-07 qingting

    #DAA#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2033496, encodeId=84e32033496cc, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Mon Oct 03 18:22:00 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779012, encodeId=14811e790124a, content=<a href='/topic/show?id=0a3d193085' target=_blank style='color:#2F92EE;'>#ADAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1930, encryptionId=0a3d193085, topicName=ADAA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Mon Jul 25 21:22:00 CST 2016, time=2016-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128603, encodeId=682612860393, content=不错哦，会学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 16 11:52:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264559, encodeId=54a9126455924, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Apr 07 04:22:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361809, encodeId=921d1361809ab, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5647, encryptionId=a88b564ea6, topicName=DAA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Apr 07 04:22:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511641, encodeId=547815116412a, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu Apr 07 04:22:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76070, encodeId=a890e60700c, content=学习了，很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Apr 06 15:55:00 CST 2016, time=2016-04-06, status=1, ipAttribution=)]
    2016-04-07 ms5236388012055669

    #拮抗剂#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2033496, encodeId=84e32033496cc, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Mon Oct 03 18:22:00 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779012, encodeId=14811e790124a, content=<a href='/topic/show?id=0a3d193085' target=_blank style='color:#2F92EE;'>#ADAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1930, encryptionId=0a3d193085, topicName=ADAA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Mon Jul 25 21:22:00 CST 2016, time=2016-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128603, encodeId=682612860393, content=不错哦，会学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 16 11:52:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264559, encodeId=54a9126455924, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Apr 07 04:22:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361809, encodeId=921d1361809ab, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5647, encryptionId=a88b564ea6, topicName=DAA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Apr 07 04:22:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511641, encodeId=547815116412a, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu Apr 07 04:22:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76070, encodeId=a890e60700c, content=学习了，很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Apr 06 15:55:00 CST 2016, time=2016-04-06, status=1, ipAttribution=)]
    2016-04-06 dhzzm

    学习了，很好

    0